Drug Trial Radar · NCT05840211
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
654
Planned (sponsor's estimate)
Start
May 8, 2023
Primary completion
Apr 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- May 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).
Conditions
- Locally Advanced or Unresectable Metastatic Breast Cancer
- Stage IV Breast Cancer
Interventions
Sacituzumab Govitecan-hziyDrug
Administered intravenously
PaclitaxelDrug
Administered intravenously
Nab-paclitaxelDrug
Administered intravenously
CapecitabineDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: Up to approximately 29 months
Locations
288 sites in 28 countries. Site status is shown where the registry gives one.
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
Chandler, Arizona
Los Angeles Hematology Oncology Medical Group
Los Angeles, California
Stanford Cancer Institute
Palo Alto, California
University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Rocky Mountain Cancer Centers, LLP
Littleton, Colorado
Yale-New Haven Hospital-Yale Cancer Center
New Haven, Connecticut
Investigational Drug Services, AdventHealth Orlando
Altamonte Springs, Florida
Florida Cancer Specialists
Brooksville, Florida
Florida Cancer Specialist
Leesburg, Florida
Florida Cancer Specialist
St. Petersburg, Florida
Piedmont Cancer Institute
Atlanta, Georgia
Georgia Cancer Specialist - Annex
Atlanta, Georgia
Northwest Georgia Oncology Centers
Marietta, Georgia
The University of Kansas Hospital
Kansas City, Kansas
Hematology Oncology Clinic
Baton Rouge, Louisiana
Saint Luke's Cancer Institute
Kansas City, Missouri
David C. Pratt Cancer Center
St Louis, Missouri
Astera Cancer Care
East Brunswick, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York
Cleveland Clinic
Cleveland, Ohio
Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio
Penn State Cancer Institute
Hershey, Pennsylvania
Magee-Womens of UPMC
Pittsburgh, Pennsylvania
Prisma Health - Upstate
Greenville, South Carolina
Tennessee Oncology, PLLC
Nashville, Tennessee
Vanderbilt University Medical Center - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
US Oncology Investigational Products Center (IPC)
Fairfax, Virginia
US Oncology Investigational Products Center (IPC)
Norfolk, Virginia
MultiCare Regional Cancer Center - Auburn
Auburn, Washington
Hospital Britanico de Buenos Aires
Buenos Aires, Argentina
Instituto de Investigaciones Clinicas de Mar del Plata
Buenos Aires, Argentina
Instituto Alexander Fleming
C.a.b.a., Argentina
Hospital Alemán
CABA, Argentina
Centro Privado de RMI Rio Cuarto S.A.
Córdoba, Argentina
Instituto de Oncología de Rosario
Rosario, Argentina
CER San Juan Centro Polivalente de Asistencia e Investigación Clínica
San Juan, Argentina
Royal Brisbane and Women's Hospital
Queensland, ME, Australia
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
Showing 40 of 288 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.